Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Adenocarcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Squamous Cell

Lung Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Pemetrexed

Tubulin Modulators

Antimitotic Agents

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Folinic Acid

Folate

Vitamin B9

Anlotinib combined with pemetrexed and carboplatin, phase I

Anlotinib combined with pemetrexed and carboplatin, phase II

Anlotinib combined with paclitaxel and carboplatin, phase I

Anlotinib combined with paclitaxel and carboplatin, phase II

Non-squamous cell lung cancer, Anlotinib Plus PC

This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin

Anlotinib combined with pemetrexed and carboplatin, phase I

Squamous cell lung cancer, Anlotinib plus TC

This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin

Anlotinib combined with paclitaxel and carboplatin, phase I

Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent

Anlotinib combined with pemetrexed and carboplatin, phase II

Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle

after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent

Anlotinib combined with paclitaxel and carboplatin, phase II

Yuankai Shi, MD

Zhaoyuan Shi

Non-small cell lung cancer has the highest morbidity and mortality in China，and platinum-based chemotherapy is the standard first-line treatment for the wild-type NSCLC,however the overall survival still less than one year.Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit, which has strong effect of anti-angiogenesis.This study is aim to evaluate the efficacy and safety of the combination regimen of anlotinib plus platinum-based chemotherapy as first-line treatment for NSCLC.

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

A Phase I/II Study of Anlotinib Combined With Platinum-based Chemotherapy as the First-line Treatment of Patients With Locally Advanced or Advanced Non-Small Cell Lung Cancer

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Chinese Academy of Medical Sciences

Vice President of Cancer Hospital Chinese Academy of Medical Sciences

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC	NCT03636685	NSCLC Adenocarcinoma Squamous Cell C...	Anlotinib combi... Anlotinib combi... Anlotinib combi... Anlotinib combi...	18 Years - 70 Years	ChineseAMS
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC	NCT03636685	NSCLC Adenocarcinoma Squamous Cell C...	Anlotinib combi... Anlotinib combi... Anlotinib combi... Anlotinib combi...	18 Years - 70 Years	ChineseAMS

Spots Global Cancer Trial Database for anlotinib combined with paclitaxel and carboplatin, phase ii